NKTR
HEALTHCARENektar Therapeutics
AI Insight
What's Moving NKTR Today?
No stock-specific AI insight has been generated for NKTR yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$21.02$109.00
$67.28
Fundamentals
Market Cap$2.2B
P/E Ratio—
EPS$-7.93
Dividend Yield—
Dividend / Share—
ROE-53.6%
Profit Margin-284.2%
Debt / Equity—
Trading
Volume549K
Avg Volume (10D)—
Shares Outstanding33.8M
NKTR News
53 articles- 3 Biotech Takeover Targets Wall Street Is Watching After the Apogee Deal247 Wall St·Jun 23, 2026
- Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Nektar Therapeutics (NKTR) And Encourages Shareholders to Reach OutACCESS Newswire·Jun 14, 2026
- A Look At Nektar Therapeutics (NKTR) Valuation After Recent Share Price VolatilityYahoo Finance·Jun 7, 2026
- Nektar Therapeutics 8-K SEC Filing: Company Details, Common Stock, and NASDAQ Listing (June 2026)Minichart·Jun 6, 2026
- A Look At Nektar Therapeutics (NKTR) Valuation After Recent Share Price PullbackSimply Wall Street·Jun 6, 2026
- What Makes Nektar Therapeutics (NKTR) a Promising Mid-Cap Healthcare StockInsider Monkey·Jun 5, 2026
- NKTR: All proposals passed; immunology pipeline advances with REZPEG entering phase III trialsTradingView·Jun 5, 2026
- Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Yahoo Finance·Jun 3, 2026
- Nektar Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference in New YorkYahoo Finance·May 27, 2026
- Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Nektar Therapeutics (NKTR) And Encourages Stockholders to Reach OutACCESS Newswire·May 27, 2026
- This Healthcare Investor Added $43 Million to a Genomics Leader Growing Volume 34%Motley Fool·May 23, 2026
- What to Know About This Fund's $10 Million Nektar Bet Ahead of a Key Phase 3 LaunchThe Motley Fool·May 23, 2026
- Assessing Nektar Therapeutics (NKTR) Valuation After Strong REZPEG Prospects And Recent Share Price MomentumYahoo Finance·May 13, 2026
- Nektar Therapeutics Establishes New Equity Distribution AgreementTipRanks·May 9, 2026
- [8-K] NEKTAR THERAPEUTICS Reports Material EventStock Titan·May 9, 2026
- Nektar Therapeutics Q1 2026 Earnings Call SummaryMoby·May 8, 2026
- Nektar Therapeutics Q1 Earnings Call HighlightsMarketbeat·May 8, 2026
- Earnings call transcript: Nektar Therapeutics Q1 2026 reveals strong cash position amid mixed stock responseInvesting.com Canada·May 8, 2026
- Nektar (NKTR) Q1 2026 Earnings TranscriptMotley Fool·May 7, 2026
- Nektar Therapeutics Reports First Quarter 2026 Financial ResultsYahoo Finance·May 7, 2026
- How The Rezpegaldesleukin Story Is Recasting The Narrative For Nektar Therapeutics (NKTR)Yahoo Finance·May 2, 2026
- Nektar to Announce Financial Results for the First Quarter on Thursday, May 7, 2026, After Close of U.S.-Based Financial MarketsYahoo Finance·Apr 28, 2026
- Bronstein, Gewirtz & Grossman LLC Urges Nektar Therapeutics Investors to Act: Class Action Filed Alleging Investor HarmGlobeNewswire Inc.·Apr 28, 2026
- Nektar Therapeutics Shares 52-Week REZOLVE-AA Data as Rezpeg Boosts SALT ≤20 Responses in Alopecia AreataMarketbeat·Apr 25, 2026
- Deadline Alert: Nektar Therapeutics (NKTR) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud LawsuitGlobeNewswire Inc.·Apr 24, 2026
- Nektar Therapeutics Announces Closing of $373.8 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional SharesYahoo Finance·Apr 23, 2026
- Nektar Therapeutics Announces Pricing of Upsized $325 Million Public OfferingYahoo Finance·Apr 22, 2026
- ROSEN, A LEADING LAW FIRM, Encourages Nektar Therapeutics Investors to Secure Counsel Before Important Deadline in Securities Class Action - NKTRGlobeNewswire Inc.·Apr 22, 2026
- INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Aquestive Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines – AQSTGlobeNewswire Inc.·Apr 21, 2026
- Pomerantz Law Firm Announces the Filing of a Class Action Against Nektar Therapeutics, Inc. and Certain Officers – NKTRGlobeNewswire Inc.·Apr 21, 2026
- INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Eos Energy Enterprises, Inc. Of Class Action Lawsuit and Upcoming Deadlines – EOSEGlobeNewswire Inc.·Apr 21, 2026
- INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Corcept Therapeutics Incorporated of Class Action Lawsuit and Upcoming Deadlines – CORTGlobeNewswire Inc.·Apr 21, 2026
- Nektar (NKTR) Moves 18.3% Higher: Will This Strength Last?Yahoo Finance·Apr 21, 2026
- Why Nektar Therapeutics Stock Rocked it TodayThe Motley Fool·Apr 20, 2026
- Nektar Therapeutics Adds To Its 129% Two-Month Run With Alopecia NewsYahoo Finance·Apr 20, 2026
- ROSEN, LEADING TRIAL ATTORNEYS, Encourages Nektar Therapeutics Investors to Secure Counsel Before Important Deadline in Securities Class Action - NKTRGlobeNewswire Inc.·Apr 19, 2026
- Bronstein, Gewirtz & Grossman LLC Urges Nektar Therapeutics Investors to Act: Class Action Filed Alleging Investor HarmGlobeNewswire Inc.·Apr 17, 2026
Price Data
Open$64.10
Previous Close$65.70
Day High$67.79
Day Low$64.10
52 Week High$109.00
52 Week Low$21.02
52-Week Range
$21.02$109.00
$67.28
Fundamentals
Market Cap$2.2B
P/E Ratio—
EPS$-7.93
Dividend Yield—
Dividend / Share—
ROE-53.6%
Profit Margin-284.2%
Debt / Equity—
Trading
Volume549K
Avg Volume (10D)—
Shares Outstanding33.8M
About Nektar Therapeutics
Nektar Therapeutics is a biopharmaceutical company. The company is headquartered in San Francisco, California with additional operations in Huntsville, Alabama and Hyderabad, India.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeCommon Stock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—